ValueTheMarkets Podcast 032 - with Maurice Treacy, Chief Commercial Officer of Open Orphan (ORPH)

By Richard Mason


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Today’s guest on the ValueTheMarkets podcast is Maurice Treacy, Chief commercial officer of Open Orphan (LSE:ORPH) The company is focused on rare disease and orphan drug pharma services and aims to achieve rapid growth through the acquisition of smaller, high-margin pharma service providers. Following on from our earlier podcast with CEO, Cathal Friel, Maurice focusses on discussing the technical side of the business.

One of the key offerings the firm is developing is the first Genomic Health Database. Maurice gives further details and outlines the need for the database as well as highlighting the opportunity this presents to Open Orphan.

All opinions expressed are those of ValueTheMarkets and the respective guests unless otherwise stated and should not be construed as investment advice or a recommendation to buy shares in any featured Company. Listeners are advised to do their own extensive research before buying shares which, as with all small-cap exploration stocks, should be viewed as high risk. Investors should also seek the advice of a qualified investment adviser or stockbroker as they deem appropriate.


In this article:


Author: Richard Mason

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Sign up for Investing Intel Newsletter